PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Clinical trial NCT04819243 · RECRUITING

Trial details

NCT number: NCT04819243
Sponsor: Samsung Medical Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Premenopausal HR+/HER2- Metastatic Breast Cancer

Start date: 2021-08-25
Primary completion: 2025-12-30
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.